Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602394 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
A NA study of Bipolar Disorder, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00602394 is a NA study of Bipolar Disorder that has completed, run by Roxane Laboratories. The registered enrollment target is 30 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00602394, a NA study of Bipolar Disorder, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
Conditions Studied
Interventions
- DRUG Lithium
Study Locations (1)
Texas
- Novum Pharmaceutical Research Services, 11248 Wilcrest Green, , Houston77042 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-05 |
| Est. Completion | 2003-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602394
The ClinicalTrials.gov registry entry for NCT00602394 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Lithium is the first listed.
NCT00602394 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00602394 about?
NCT00602394 is a clinical study titled "Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions". The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
What is the current status of trial NCT00602394?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2003-05. Estimated completion is 2003-05.
What conditions does trial NCT00602394 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00602394?
The interventions under investigation include: Lithium (DRUG).
Who is sponsoring clinical trial NCT00602394?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00602394 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder
RECRUITING · NA
-
Healthy Lifestyles in Bipolar Disorder: Bay Area Study
RECRUITING · NA
-
A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder
RECRUITING · NA
-
Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.